Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 12/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23977662 | 1.00 | KAT2B (0.39) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL22303403 | 1.00 | KAT2B (0.39) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18233551 | 0.94 | KAT2B (0.43) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL14472668 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL20621874 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18236735 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL22055532 | 0.83 | GAA (0.42) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18183344 | 0.83 | KDM4E (0.40) | KAT2BKDM4EALDH1A1GAAL3MBTL1 | |
| SCHEMBL19720601 | 0.80 | KAT2B (0.40) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL20079253 | 0.80 | KAT2B (0.40) | KAT2BBPTFKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10975076-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2017189829-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9802915-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975076-B2 | Compositions, uses and methods for making them | BAX, CASP3, CASP7 | KAT2B 2366/4885BPTF 3131/4885KDM4E 1957/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | KAT2B 694/4885BPTF 3431/4885KDM4E 1641/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | KAT2B 1079/4885BPTF 2261/4885KDM4E 449/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | KAT2B 1079/4885BPTF 2261/4885KDM4E 449/4885 |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | KAT2B 1079/4885BPTF 2261/4885KDM4E 449/4885 |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885BPTF 15/4885KDM4E 1061/4885 |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | KAT2B 3136/4885BPTF 2043/4885KDM4E 1534/4885 |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | KAT2B 3136/4885BPTF 2043/4885KDM4E 1534/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | KAT2B 1079/4885BPTF 2261/4885KDM4E 449/4885 |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | KAT2B 3136/4885BPTF 2043/4885KDM4E 1534/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | KAT2B 3317/4885BPTF 4726/4885KDM4E 2952/4885 |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | KAT2B 3136/4885BPTF 2043/4885KDM4E 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.